GenKyoTex's Reverse Merger Round

GenKyoTex raised a round of funding on December 22, 2016. Investors include Genticel.

GenKyoTex is developing first-in-class, small molecule therapeutics that selectively inhibit the NOX family of enzymes. Using a screening platform, GenKyoTex has identified NOX inhibitors with the pot…

Articles about GenKyoTex's Reverse Merger Round: